ArticleAnnals of surgery2000
Fas and Fas-ligand expression in human pancreatic cancer.
Article in Annals of surgery, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort.International journal of cancer · 2026Article
- Serum Levels of Soluble Forms of Fas and FasL in Patients with Pancreatic and Papilla of Vater Adenocarcinomas.Cancers · 2025Article
- Gemcitabine and Flurbiprofen Enhance Cytotoxic Effects on Cancer Cell Lines Mediated by Mesenchymal Stem Cells.International journal of molecular sciences · 2025Article
- Article
- Polymorphonuclear Neutrophils and Tumors: Friend or Foe?Experientia supplementum (2012) · 2022Article
- Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle.Acta pharmaceutica Sinica. B · 2022Review
- A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.The Journal of experimental medicine · 2020Article
- Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3.Scientific reports · 2020Article
- Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.CPT: pharmacometrics & systems pharmacology · 2018Article
- Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy.Translational cancer research · 2017Article
- Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers.Journal of immunology research · 2017Review
- Article
- Reduced expression of caspase-8 and cleaved caspase-3 in pancreatic ductal adenocarcinoma cells.Oncology letters · 2016Article
- Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.PloS one · 2014Article
- Article
- Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.Molecular cancer therapeutics · 2010Article
- Apoptotic pathways in pancreatic ductal adenocarcinoma.Molecular cancer · 2008Review
- Immunotherapy for pancreatic cancer - science driving clinical progress.Nature reviews. Cancer · 2005Review
- A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.Virchows Archiv : an international journal of pathology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
objectiveTo investigate Fas and FasL expression in pancreatic tissues and cultured pancreatic cancer cell lines, and to assess the ability of anti-Fas antibodies to induce apoptosis. SUMMARY BACKGROUND DATA: Activation of the Fas receptor by Fas-ligand (FasL) results in apoptosis, and dysregulation of this pathway may contribute to abnormal cell proliferation.
methodsNorthern blotting and immunohistochemistry were used to compare Fas and FasL expression in normal and cancerous tissues. DNA 3'-OH end labeling was used to detect apoptotic cells. The effects of Fas activation on cell growth and signaling pathways were investigated in culture.
resultsPancreatic cancers exhibited increased Fas RNA levels, whereas FasL mRNA levels were similar in both groups. Despite the colocalization of Fas and FasL in the cancer cells, an apoptotic signal was present in approximately 10% of these cells in only 2 of 16 cancer samples. Fas and FasL were coexpressed in all four cell lines, whereas Fas-associated phosphatase 1 was below the level of detection in all cell lines. Only COLO-357 cells underwent apoptosis after Fas activation. Apoptosis was associated with enhanced activation of jun kinase (JNK) and p38 mitogen-activated protein kinase (MAPK). In the presence of actinomycin D, Fas antibody also induced apoptosis in the other three cell lines.
conclusionsThese results suggest that pancreatic cancer cells are resistant to Fas-mediated apoptosis by mechanisms excluding receptor downregulation or Fas-associated phosphatase upregulation and raise the possibility that Fas-mediated apoptosis may be dependent on the activation of the JNK/p38 MAPK pathway in these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.